This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2018 Jan 11;378(2):158-168.

doi: 10.1056/NEJMra1703481.

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A Postow¹, Robert Sidlow¹, Matthew D Hellmann¹

Affiliations

PMID: 29320654
DOI: 10.1056/NEJMra1703481

Review

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A Postow et al. N Engl J Med. 2018.

. 2018 Jan 11;378(2):158-168.

doi: 10.1056/NEJMra1703481.

Authors

Michael A Postow¹, Robert Sidlow¹, Matthew D Hellmann¹

Affiliation

¹ From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.

PMID: 29320654
DOI: 10.1056/NEJMra1703481

No abstract available

PubMed Disclaimer

Comment in

Adverse Events Associated with Immune Checkpoint Blockade.
Jhaveri KD, Perazella MA. Jhaveri KD, et al. N Engl J Med. 2018 Mar 22;378(12):1163. doi: 10.1056/NEJMc1801663. N Engl J Med. 2018. PMID: 29565518 No abstract available.
Adverse Events Associated with Immune Checkpoint Blockade.
Akturk HK, Michels AW. Akturk HK, et al. N Engl J Med. 2018 Mar 22;378(12):1163-4. doi: 10.1056/NEJMc1801663. N Engl J Med. 2018. PMID: 29565519 No abstract available.
Adverse Events Associated with Immune Checkpoint Blockade.
Kumar B, Ballas Z. Kumar B, et al. N Engl J Med. 2018 Mar 22;378(12):1164. doi: 10.1056/NEJMc1801663. N Engl J Med. 2018. PMID: 29565520 Free PMC article. No abstract available.
Adverse Events Associated with Immune Checkpoint Blockade.
Cohen Tervaert JW, Ye C, Yacyshyn E. Cohen Tervaert JW, et al. N Engl J Med. 2018 Mar 22;378(12):1164-5. doi: 10.1056/NEJMc1801663. N Engl J Med. 2018. PMID: 29565521 No abstract available.

Similar articles

[Toxicity of immune checkpoints inhibitors].
Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J. Delaunay M, et al. Rev Mal Respir. 2018 Dec;35(10):1028-1038. doi: 10.1016/j.rmr.2017.08.006. Epub 2018 Sep 10. Rev Mal Respir. 2018. PMID: 30213624 Review. French.
[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].
Faviez G, Bousquet E, Rabeau A, Rouquette I, Collot S, Goumarre C, Meyer N, Prevot G, Mazieres J. Faviez G, et al. Rev Mal Respir. 2018 Nov;35(9):963-967. doi: 10.1016/j.rmr.2018.08.003. Epub 2018 Sep 13. Rev Mal Respir. 2018. PMID: 30220489 French.
Immunotherapy Toxicities.
Sanchez K, Page DB, Urba W. Sanchez K, et al. Surg Oncol Clin N Am. 2019 Jul;28(3):387-401. doi: 10.1016/j.soc.2019.02.009. Epub 2019 Apr 5. Surg Oncol Clin N Am. 2019. PMID: 31079795 Review.
[Immunotherapies of cancer: Is there any impact on patient cognitive functions?].
Castel H, Joly F. Castel H, et al. Med Sci (Paris). 2020 Aug-Sep;36(8-9):695-699. doi: 10.1051/medsci/2020139. Epub 2020 Aug 21. Med Sci (Paris). 2020. PMID: 32821042 French. No abstract available.
[No title available]
[No authors listed] [No authors listed] Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(4):263a. doi: 10.2177/jsci.40.263a. Nihon Rinsho Meneki Gakkai Kaishi. 2017. PMID: 29176294 Japanese. No abstract available.

See all similar articles

Cited by

Immune-oncology targets and therapeutic response of cell pyroptosis-related genes with prognostic implications in neuroblastoma.
Liu X, Xu Z, Yin H, Zhao X, Duan J, Zhou K, Shen Q. Liu X, et al. Discov Oncol. 2024 Nov 15;15(1):661. doi: 10.1007/s12672-024-01518-8. Discov Oncol. 2024. PMID: 39548036
Immune-related adverse events in cancer patients referred to the palliative care team of a tertiary care center: a retrospective observational study.
Yanaizumi R, Nagamine Y, Harada S, Goto T. Yanaizumi R, et al. Support Care Cancer. 2024 Nov 15;32(12):793. doi: 10.1007/s00520-024-09012-1. Support Care Cancer. 2024. PMID: 39542927
A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade.
Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Fernandez LT, Saggau J, Bonasera D, Kiljan M, Gozum G, Lichius L, Cai J, Niu LN, Caiaffa MI, Herter JM, Walczak H, Liccardi G, Grüll H, Büttner R, Bosco G, George J, Thomas RK, Bozek K, Reinhardt HC, Herter-Sprie GS. Ibruli O, et al. J Cancer Res Clin Oncol. 2024 Nov 14;150(11):496. doi: 10.1007/s00432-024-05942-9. J Cancer Res Clin Oncol. 2024. PMID: 39542886 Free PMC article.
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.
Wang S, Zhang R, Wang S, Guo Q, Yin D, Song Y, She X, Wang X, Duan J. Wang S, et al. Front Pharmacol. 2024 Oct 29;15:1309148. doi: 10.3389/fphar.2024.1309148. eCollection 2024. Front Pharmacol. 2024. PMID: 39534085 Free PMC article.
In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy.
Mao C, Deng F, Zhu W, Xie L, Wang Y, Li G, Huang X, Wang J, Song Y, Zeng P, He Z, Guo J, Suo Y, Liu Y, Chen Z, Yao M, Zhang L, Shen J. Mao C, et al. Nat Commun. 2024 Nov 9;15(1):9723. doi: 10.1038/s41467-024-54081-9. Nat Commun. 2024. PMID: 39521768 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations